Treatment of non-genotype 1 hepatitis C virus patients

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalCurrent Gastroenterology Reports
Volume14
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Hepacivirus
Genotype
Ribavirin
Therapeutics
Interferons
Antiviral Agents

Keywords

  • Direct acting antivirals
  • HCV genotype 2
  • HCV genotype 3
  • HCV genotype 4
  • Individualized Treatment
  • Peg-IFN
  • Ribavirin
  • Short treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of non-genotype 1 hepatitis C virus patients. / Mangia, Alessandra; Mottola, Leonardo.

In: Current Gastroenterology Reports, Vol. 14, No. 1, 02.2012, p. 87-93.

Research output: Contribution to journalArticle

@article{e9e7157d19a44fd9808bec5f3c11534c,
title = "Treatment of non-genotype 1 hepatitis C virus patients",
abstract = "The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.",
keywords = "Direct acting antivirals, HCV genotype 2, HCV genotype 3, HCV genotype 4, Individualized Treatment, Peg-IFN, Ribavirin, Short treatment",
author = "Alessandra Mangia and Leonardo Mottola",
year = "2012",
month = "2",
doi = "10.1007/s11894-011-0235-3",
language = "English",
volume = "14",
pages = "87--93",
journal = "Current Gastroenterology Reports",
issn = "1522-8037",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Treatment of non-genotype 1 hepatitis C virus patients

AU - Mangia, Alessandra

AU - Mottola, Leonardo

PY - 2012/2

Y1 - 2012/2

N2 - The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.

AB - The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.

KW - Direct acting antivirals

KW - HCV genotype 2

KW - HCV genotype 3

KW - HCV genotype 4

KW - Individualized Treatment

KW - Peg-IFN

KW - Ribavirin

KW - Short treatment

UR - http://www.scopus.com/inward/record.url?scp=84857366135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857366135&partnerID=8YFLogxK

U2 - 10.1007/s11894-011-0235-3

DO - 10.1007/s11894-011-0235-3

M3 - Article

VL - 14

SP - 87

EP - 93

JO - Current Gastroenterology Reports

JF - Current Gastroenterology Reports

SN - 1522-8037

IS - 1

ER -